Royalty Report: Drugs, Cancer, Delivery – Collection: 27197


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Delivery
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Biotechnology
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27197

License Grant
We signed a license agreement to develop and commercialize liposome encapsulated paclitaxel (LEP).
License Property
LEP allows cancer patients to tolerate higher dosages of chemotherapy, providing greater therapeutic value in a number of types of cancer tumors; liposome compounds worldwide; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs.  This membrane encapsulation feature of liposomes enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug.  We initiated a Phase I clinical study on LEP in September of 1998 for patients with lung cancer.
Field of Use
The rights granted apply to cancer.

IPSCIO Record ID: 27226

License Grant
We signed a licensee agreement to develop and commercialize liposome encapsulated doxorubicin (LED), liposome compounds worldwide.

LED allows cancer Phase I Breast, Prostate, 2 Patents patients to tolerate higher completed, Hematological dosages of chemotherapy initiated providing greater therapeutic Phase II in value in a number of types of June 1998 cancer tumors; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs.  This membrane encapsulation feature of liposome enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug – clinical trial.  Pursuant to the license agreement, the Licensee agreed to assume all further responsibility for, and the costs associated with, the further development and testing of LED and LEP and the obtaining of all regulatory approvals.

IPSCIO Record ID: 993

License Grant
Two pharma entered into an exclusive worldwide licensing agreement for the development and commercialization of Opaxio (Xyotax). The agreement also provides an option to develop and commercialize pixantrone based on agreed terms.
License Property
Opaxio is a bioengineered version of paclitaxel, links paclitaxel to a large macro molecule called polyglutamate, which is a polypeptide. This molecule is essentially inactive in bloodstream. Therefore you don't have free levels of paclitaxel circulating. That molecule has to be uptaken by cells and then undergo digestion in endosomes and lysosomes. That's where the paclitaxel is released.  That gives you a property that is uniquely different than any formulation of paclitaxel, in addition to a rapid infusion, water soluble without premeds and other requirements. Most importantly, we see very little if any hair loss, very little if any, less than 2%, grade 3/4 neutropenia.  So it really changes the face of chemotherapy for patients who are receiving it.  OPAXIO was designed to deliver paclitaxel preferentially to tumor tissue. By linking paclitaxel to a biodegradable amino acid carrier, the conjugated chemotherapeutic agent is inactive in the bloodstream, sparing normal tissues the toxic side effects of chemotherapy. Once inside tumor tissue the conjugated chemotherapeutic agent is activated and released by the action of an enzyme called cathepsin B. The activity of this enzyme and thus the rate of release of paclitaxel poliglumex is increased in the presence of estrogen.
Field of Use
Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

IPSCIO Record ID: 28952

License Grant
Licensor grants to the Licensee a worldwide, exclusive license under the Licensed Proprietary Property to make, use or sell Products for the Field of Use. Licensor shall not license any other party rights to deliver camptothecin or analogues thereof, alone or in combination with another drug, in liposomes, lipid complexes or other liposome particles, to the respiratory tract via aerosol droplets. Licensor grants the right to grant sub-licenses to others within the scope of and under the terms and conditions of the License.
License Property
Licensor is the owner of certain inventions, discoveries, and know-how comprising certain Proprietary Property related to Camptothecin delivery.

Camptothecin is a cytotoxic quinoline alkaloid discovered in the screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China used as a cancer treatment in Traditional Chinese Medicine, showing anticancer activity in preliminary clinical trials but also low solubility and (high) adverse drug reaction. CPT analogues have been approved and are used in cancer chemotherapy.

The license is for the rights to deliver paclitaxel or analogues thereof, alone or in combination with another drug, in liposomes, lipid complexes or other liposome particles, to the respiratory tract via aerosol droplets.

The methods, composition, and information claimed in U.S. Patent No. 5,049,388, entitled Small Particle Aerosol Liposome and Liposome-Drug Combinations for Medical Use and U.S. Patent Application Serial No. 08/933,254, entitled Small Particle Liposome Aerosols for Delivery of Anti-Cancer Drugs.

Field of Use
These are used for Cancer therapy in humans wherein paclitaxel or analogues thereof are delivered in liposomes, lipid complexes, or other liposome particles, to the respiratory tract via aerosol droplets.

IPSCIO Record ID: 3957

License Grant
The Licensor granted the Licensee an exclusive License under certain patents to commercialize the Optisome products for all uses throughout the world, and an exclusive License under certain patents held by the Licensor to commercialize the Optisome products for all uses throughout the world under the terms of certain research Agreements between the Licensor and the British Columbia Cancer Agency, and an exclusive License to all technical information and know-how relating to the technology claimed in the patents held exclusively by the Licensor and to all confidential information relating to the Optisome products to commercialize the Optisome products for all uses throughout the world.
License Property
Optisomes are a new generation of unique, sphingomyelin/cholesterol-based nanoparticles designed to encapsulate cell cycle-specific chemotherapeutic to improve efficacy and reduce toxicity. Optisomes are approximately 100 nanometers in diameter and able to encapsulate and transport cancer drugs preferentially to tumor sites. While too large to easily migrate out of normal blood vessels, Optisomes are able to migrate across the more leaky vasculature of a tumor, resulting in higher concentrations of drugs at tumor sites than in normal tissue. Optisomes' unique sphingomyelin-cholesterol composition is particularly well suited to cell cycle-specific agents such as vincristine, vinorelbine and topotecan. The relative rigidity of the Optisomes' outer shell results in a long circulating half-life and sustained drug release at the tumor site, which may increase tumor cell exposure during the most vulnerable phases of cell division. Combined, these factors are key to the Optisome advantage as sustained drug exposure increases tumor cell death.
Field of Use
The Licensee has the right to grant subLicenses to third parties and in such event the parties will share sublicensing revenue received by us at varying rates for each Optisome product depending on such Optisome product’s stage of clinical development.  Under the License Agreement, we also granted back to the Licensor a limited, royalty-free, non-exclusive License in certain patents and technology owned or Licensed to us solely for use in developing and commercializing liposomes having an active agent encapsulated, intercalated or entrapped therein.  Licensee's Optisome pipeline includes Marqibo(r) (vincristine), Alocrest(tm) (vinorelbine) and Brakiva(tm) (topotecan).

IPSCIO Record ID: 179238

License Grant
Licensor and Licensee entered into a 10 year exclusive License Agreement entitling it to use the Novavax Technologies in the fields.
License Property
Novavax Technologies proprietary organized lipid structures, lipid vesicle encapsulation technologies, cellulose structures and micellar nanoparticles, that have a wide variety of applications in human vaccines and pharmaceuticals.

Liposome encapsulation is a process designed to entrap and deliver various useful materials. Prior to the development of the Novavax Technologies, the most commonly used technology, phospholipid liposome encapsulation, had a limited capacity to encapsulate anything other than materials that can be dissolved or suspended in water. Phospholipid liposomes are man-made, microscopic spheres that are usually formed through a multi-step process, which generally includes the mixing of water, organic solvents and phospholpids. Most phospholipid-based liposomes are produced from materials that are expensive and may require the use of potentially hazardous organic solvents. The standard, multi-step phospholipid manufacturing process yields small quantities of expensive, less stable vesicles with limited cargo capacity.

Field of Use
This agreement pertains to the drug industry relating to therapeutic products for human infectious diseases, including new vaccines, new adjuvants for vaccines, anti-bacterial and anti-viral products and formulations for topical drug delivery in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals.

IPSCIO Record ID: 223861

License Grant
The Taiwanese Licensor granted the Taiwanese Licensee the exclusive right to produce and promote LIPO-DOX, a medicinal product developed by the Licensor.
License Property
Lipo-Dox is a liposomal encapsulated doxorubicin product for the treatment of breast cancer, ovarian cancer, and AIDS-related Kaposi’s sarcoma and multiple myeloma.  Lipo-Dox, with its PEGylated liposomes design, reduces the rate at which the active substance is broken down, allowing it to circulate in the blood for a longer period of time. Lipo-Dox also reduces effects on non-cancer tissues and cells, hence has reduced cardiotoxicity compared to free form doxorubicin.
Field of Use
The Licensee will manufacture and distribute the product in Taiwan.

IPSCIO Record ID: 314332

License Grant
Licensor grants to the Licensee of Denmark and its Affiliates a worldwide, exclusive license, with the right to sublicense, to the Licensed Patents and Licensed Know-How, to research, develop, make, have made, use, import, export, sell, offer for sale, and otherwise transfer the Licensed Product in the Territory.

Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoam® delivery system in order to develop and commercialize  formulations of Liraglutide.

License Property
Licensor is a biopharmaceutical company specializing in the discovery, development and commercialization of DepoFoam® a proprietary injectable sustained-release delivery system (multivesicular liposomes).

Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.

Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.

Field of Use
DepoFoam is a drug delivery technology which consists of multi-vesicular liposome particles that contain internal chambers for encapsulated drugs. DepoFoam is capable of sustained release of a drug over a period of between one and 30 days. It works with narrow gauge needles and pen systems and offers flexible delivery that can be designed to for an immediate release dose followed by sustained delivery.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.